Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vokes, E. E.
Right arrow Articles by Green, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vokes, E. E.
Right arrow Articles by Green, M. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 20 (October), 2002: 4191-4198
© 2002 American Society for Clinical Oncology

Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431

By Everett E. Vokes, James E. Herndon, II, Jeffrey Crawford, Kenneth A. Leopold, Michael C. Perry, Antonius A. Miller, Mark R. Green

From the University of Chicago Medical Center and Cancer and Leukemia Group B, Chicago, IL; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Duke Medical Center, Durham, NC; University of Missouri, Columbia, MO; University of Tennessee, Memphis, TN; and Medical University of South Carolina, Charleston, SC.

Address reprint requests to Everett E. Vokes, MD, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637-1470; email: evokes{at}medicine.bsd.uchicago.edu

PURPOSE: To evaluate new drugs in combination with cisplatin in unresectable stage III non–small-cell lung cancer, Cancer and Leukemia Group B (CALGB) conducted a randomized phase II study of two cycles of induction chemotherapy followed by two additional cycles of the same drugs with concomitant radiotherapy.

PATIENTS AND METHODS: Eligible patients received four cycles of cisplatin at 80 mg/m2 on days 1, 22, 43, and 64 with arm 1: gemcitabine 1,250 mg/m2 on days 1, 8, 22, and 29 and 600 mg/m2 on days 43, 50, 64, and 71; arm 2: paclitaxel 225 mg/m2 for 3 hours on days 1 and 22 and 135 mg/m2 on days 43 and 64; and arm 3: vinorelbine 25 mg/m2 on days 1, 8, 15, 22, and 29 and 15 mg/m2 on days 43, 50, 64, and 71. Radiotherapy was initiated on day 43 at 2 Gy/d (total dose, 66 Gy).

RESULTS: One hundred seventy-five eligible patients were analyzed. Toxicities during induction chemotherapy consisted primarily of grade 3 or 4 granulocytopenia. Grade 3 or 4 toxicities during concomitant chemoradiotherapy consisted of thrombocytopenia, granulo-cytopenia, and esophagitis. Response rates after completion of radiotherapy were 74%, 67%, and 73% for arms 1, 2, and 3, respectively. Median survival for all patients was 17 months. One-, 2-, and 3-year survival rates for the patients on the three arms were 68%/37%/28%, 62%/29%/19%, and 65%/40%/23%.

CONCLUSION: Four cycles of gemcitabine, vinorelbine, or paclitaxel in combination with cisplatin can be administered at these doses and schedules. The observed survival rates exceed those of previous CALGB trials and may be attributable to the use of concomitant chemoradiotherapy. Induction chemotherapy added to concomitant chemoradiotherapy is being evaluated in a phase III randomized trial.

Presented in part at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, May 15-18, 1999, and the Thirty-Third Annual Meeting of ASCO, Denver, CO, May 17-20, 1997.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
N. Hanna, M. Neubauer, C. Yiannoutsos, R. McGarry, J. Arseneau, R. Ansari, C. Reynolds, R. Govindan, A. Melnyk, W. Fisher, et al.
Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology
J. Clin. Oncol., December 10, 2008; 26(35): 5755 - 5760.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
M. J. Edelman, M. Suntharalingam, W. Burrows, K. F. Kwong, N. Mitra, Z. Gamliel, M. Riley, L. B. Cooper, N. L. Kennedy, S. Buskirk, et al.
Phase I/II Trial of Hyperfractionated Radiation and Chemotherapy Followed by Surgery in Stage III Lung Cancer
Ann. Thorac. Surg., September 1, 2008; 86(3): 903 - 910.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Herndon II, A. B. Kornblith, J. C. Holland, and E. D. Paskett
Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials
J. Clin. Oncol., September 1, 2008; 26(25): 4116 - 4123.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, A. W. Blackstock, J. A. Bogart, X. Wang, M. Munley, J. Rosenman, L. Gu, G. A. Masters, P. Ungaro, A. Sleeper, et al.
Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non-Small-Cell Lung Cancer: CALGB 30105
J. Clin. Oncol., May 20, 2008; 26(15): 2457 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
N. Pourel, N. Santelmo, N. Naafa, A. Serre, W. Hilgers, L. Mineur, N. Molinari, and F. Reboul
Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response
Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 829 - 836.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Shewach and T. S. Lawrence
Antimetabolite Radiosensitizers
J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. W. Blackstock and R. Govindan
Definitive Chemoradiation for the Treatment of Locally Advanced Non Small-Cell Lung Cancer
J. Clin. Oncol., September 10, 2007; 25(26): 4146 - 4152.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes, J. E. Herndon II, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. Neill, J. N. Atkins, D. M. Watson, W. Akerley, and M. R. Green
Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B
J. Clin. Oncol., May 1, 2007; 25(13): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Sekine, M. Sumi, Y. Ito, T. Kato, Y. Fujisaka, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura
Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., April 23, 2007; (2007) hym008v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F Mornex and N Girard
Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art
Ann. Onc., December 1, 2006; 17(12): 1743 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Huber, M. Flentje, M. Schmidt, B. Pollinger, H. Gosse, J. Willner, and K. Ulm
Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group
J. Clin. Oncol., September 20, 2006; 24(27): 4397 - 4404.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green
The cancer and leukemia group B respiratory committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Bogart, S. L. Seagren, and A. Glicksman
Radiation oncology research in the cancer and leukemia group B.
Clin. Cancer Res., June 1, 2006; 12(11): 3628s - 3634s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. G. Divers, S. A. Spencer, D. Carey, E. M. Busby, M. D. Hyatt, and F. Robert
Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6664 - 6673.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes
Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 5853 - 5855.
[Full Text] [PDF]

Home page
 JCOHome page
P. Fournel, G. Robinet, P. Thomas, P.-J. Souquet, H. Lena, A. Vergnenegre, J.-Y. Delhoume, J. Le Treut, J.-A. Silvani, E. Dansin, et al.
Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study
J. Clin. Oncol., September 1, 2005; 23(25): 5910 - 5917.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. P. Belani, H. Choy, P. Bonomi, C. Scott, P. Travis, J. Haluschak, and W. J. Curran Jr
Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol
J. Clin. Oncol., September 1, 2005; 23(25): 5883 - 5891.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E. Vokes, J. Crawford, J. Bogart, M. A. Socinski, G. Clamon, and M. R. Green
Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 5045s - 5050s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Farray, N. Mirkovic, and K. S. Albain
Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3257 - 3269.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken
Combined Modality Therapy of Gemcitabine and Radiation
Oncologist, January 1, 2005; 10(1): 34 - 51.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, D. E. Morris, J. S. Halle, D. T. Moore, T. A. Hensing, S. A. Limentani, R. Fraser, M. Tynan, A. Mears, M. P. Rivera, et al.
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non-Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
J. Clin. Oncol., November 1, 2004; 22(21): 4341 - 4350.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes
Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck
Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. A. Socinski, C. Zhang, J. E. Herndon II, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, J. Crawford, M. C. Perry, S. L. Seagren, et al.
Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
Ann. Onc., July 1, 2004; 15(7): 1033 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, Y. Watanabe, H. Wada, M. Tsuboi, N. Hamajima, et al.
A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung
N. Engl. J. Med., April 22, 2004; 350(17): 1713 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 The OncologistHome page
G. V. Scagliotti and A. T. Turrisi III
Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
Oncologist, August 1, 2003; 8(4): 361 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen
A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. R. Gandara, K. Chansky, K. S. Albain, B. R. Leigh, L. E. Gaspar, P. N. Lara Jr, H. Burris, P. Gumerlock, J. P. Kuebler, J. D. Bearden III, et al.
Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non-Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504
J. Clin. Oncol., May 15, 2003; 21(10): 2004 - 2010.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online